贝丝-以色列-迪肯尼斯医疗中心获NIH 300万美元资助 寻找心脏疾病新型生物标志物

  近日，美国国立卫生研究院计划奖励贝丝-以色列-迪肯尼斯医疗中心（Beth Israel Deaconess Medical Center，BIDMC）300万美元，这笔资金将支持BIDMC进行II期研究，即寻找可以用于预测心脏疾病患者预后的新型microRNAs。
  这项资助是继2013年NIH资助400万美元的又一项资助计划，截至目前为止，该研究小组已经鉴别出了一系列miRNA候选生物标志物，其中就包括miR-30d，早在今年年初研究者就发现生物标志物miR-30d可以作为心脏病患者心脏重塑的一种有益的预测子，同时miR-30d还是抑制患者机体心脏细胞死亡的主要角色。
  在NIH这项资助的帮助下，研究人员将在后期研究中证实miR-30d的作用及作用机制，同时也可以进行大量病人群体的研究来发现其它的候选miRNAs；BIDMC的研究者Saumya Das教授表示，在过去两年里，我们已经利用RNA测序技术鉴别了患者机体血浆中细胞外RNAs的特性，这就可以帮助我们更好地理解病人心脏病发作后的预后情况。
  研究者的最终目的就是利用基于microRNA的测试技术来帮助预测哪些患者会在心脏重塑后发生高风险的并发症，这对于我们后期监测患者预后情况，并且利用合适的药物疗法或植入式设备来干预患者治疗或将带来巨大帮助。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

NIH Awards Beth Israel Team $3M to Continue Study of Heart Disease Biomarkers

The National Institutes of Health has awarded a Beth Israel Deaconess Medical Center (BIDMC) research team $3 million in funding to support the second phase of an effort to identify microRNAs that can be used to predict clinical outcomes of heart disease patients.

The grant, which was awarded under the NIH's Extracellular RNA Communication program, follows a $4 million award the group received to kick off the project in 2013.

To date, the team has identified a number of miRNA biomarker candidates including miR-30d, which the researchers reported earlier this year as a predictor of beneficial cardiac remodeling in patients following a heart attack and a key player in preventing cell death.

With the latest grant, the investigators aim to validate miR-30d and other candidate miRNAs in several large patient cohorts.

"Over the past two years, we have been using RNA sequencing technology to identify characteristics in extracellular RNAs in plasma that might enable us to better predict patient outcomes following a heart attack," Saumya Das, a BIDMC researcher and principal investigator of the grant, said in a statement. "Our ultimate goal is to use microRNA-based tests to predict which patients might be at risk of complications related to remodeling. That way we can more aggressively monitor their conditions and intervene with medications or implantable devices if needed."

Collaborating with Das and his BIDMC colleagues are collaborators from Brigham and Women's Hospital and Massachusetts General Hospital.